XORTX Therapeutics Inc. (XRTX.V)
CAD 1.62
(-7.43%)
CAD 1.62
(-7.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.85 Million CAD | 59.09% |
| 2022 | -6.98 Million CAD | -439.31% |
| 2021 | -1.29 Million CAD | -0.88% |
| 2020 | -1.28 Million CAD | -104.04% |
| 2019 | -629.57 Thousand CAD | 83.33% |
| 2018 | -3.77 Million CAD | -696.27% |
| 2017 | -474.2 Thousand CAD | -14.31% |
| 2016 | -414.83 Thousand CAD | 0.0% |
| 2014 | -36.92 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.01 Million USD | -211.84% |
| 2024 Q2 | 170.06 Thousand USD | 105.63% |
| 2023 Q2 | -1.69 Million USD | 7.65% |
| 2023 FY | -2.91 Million CAD | 58.32% |
| 2023 Q3 | -1.33 Million USD | 21.19% |
| 2023 Q4 | 2.69 Million USD | 302.44% |
| 2023 Q1 | -1.83 Million USD | 37.22% |
| 2022 Q2 | -1.58 Million CAD | 53.81% |
| 2022 Q1 | -3.42 Million CAD | -137.64% |
| 2022 Q4 | -2.91 Million CAD | -86.77% |
| 2022 Q3 | -1.56 Million CAD | 1.19% |
| 2022 FY | -6.98 Million CAD | -439.31% |
| 2021 FY | -1.29 Million CAD | -0.88% |
| 2021 Q4 | 9.09 Million CAD | 208.85% |
| 2021 Q2 | -218.44 Thousand CAD | 89.95% |
| 2021 Q1 | -2.17 Million CAD | -380.08% |
| 2021 Q3 | -8.35 Million CAD | -3724.57% |
| 2020 Q4 | -452.72 Thousand CAD | -6.55% |
| 2020 Q2 | -373.73 Thousand CAD | -1024.66% |
| 2020 Q1 | -33.23 Thousand CAD | 82.46% |
| 2020 FY | -1.28 Million CAD | -104.04% |
| 2020 Q3 | -424.91 Thousand CAD | -13.69% |
| 2019 Q1 | -152.83 Thousand CAD | -3.64% |
| 2019 FY | -629.57 Thousand CAD | 83.33% |
| 2019 Q2 | -155.41 Thousand CAD | -1.69% |
| 2019 Q4 | -189.46 Thousand CAD | -43.7% |
| 2019 Q3 | -131.85 Thousand CAD | 15.16% |
| 2018 Q1 | -3.04 Million CAD | -1104.9% |
| 2018 Q4 | -147.46 Thousand CAD | 51.94% |
| 2018 Q2 | -274.87 Thousand CAD | 90.98% |
| 2018 Q3 | -306.82 Thousand CAD | -11.62% |
| 2018 FY | -3.77 Million CAD | -696.27% |
| 2017 Q1 | -66.17 Thousand CAD | -15.13% |
| 2017 FY | -474.2 Thousand CAD | -14.31% |
| 2017 Q4 | -252.86 Thousand CAD | -190.33% |
| 2017 Q3 | -87.09 Thousand CAD | -83.43% |
| 2017 Q2 | -47.48 Thousand CAD | 28.25% |
| 2016 FY | -414.83 Thousand CAD | 0.0% |
| 2016 Q4 | -57.47 Thousand CAD | -10.37% |
| 2016 Q3 | -52.07 Thousand CAD | -17.8% |
| 2016 Q2 | -44.2 Thousand CAD | -425.13% |
| 2016 Q1 | 13.59 Thousand CAD | 112.47% |
| 2015 Q1 | -17.39 Thousand CAD | -171.9% |
| 2015 Q2 | -62.62 Thousand CAD | -259.93% |
| 2015 Q4 | -109.05 Thousand CAD | -134.24% |
| 2015 Q3 | -46.55 Thousand CAD | 25.66% |
| 2014 Q3 | -6678.00 CAD | -3.6% |
| 2014 FY | -36.92 Thousand CAD | 0.0% |
| 2014 Q2 | -6446.00 CAD | 0.0% |
| 2014 Q4 | -6399.00 CAD | 4.18% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | 14.049% |
| Covalon Technologies Ltd. | -4.46 Million CAD | 35.903% |
| Hemostemix Inc. | -2.5 Million CAD | -14.278% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 72.758% |
| Kane Biotech Inc. | -5.03 Million CAD | 43.2% |
| MedMira Inc. | -2.67 Million CAD | -6.866% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -24.788% |
| NervGen Pharma Corp. | -22.38 Million CAD | 87.225% |